UPDATE ON WHO CLASSIFICATION OF LYMPHOMA


Andrew Wotherspoon Consultant Histopathologist Royal Marsden Hospital




Lymphoma Classification

- A language for communication between individuals practising the same discipline
- Histopathologically based
- Reproducible
- Clinically relevant
- Sufficiently flexible to allow updating

Getting to where we are today





Principles of the REAL/WHO Classification

- Morphology
 - May be sufficient for diagnosis in many cases
- Immunophenotype and Genetics
 - Often helpful in differential diagnosis
 - Have played a major role in defining disease entities
- Clinical features
 - Play an important part in disease definition
 - Nodal and extranodal neoplasms are not equivalent
- Postulated normal cell counterpart
 - Helpful but not always possible
 - Cannot be the sole basis for classification
- The relative importance of each feature varies among diseases no "gold standard."

Principles of the WHO Classification

- 2008 classification emphasises in addition the importance of:
- Anatomic site
 - MALT lymphoma vs lymphoplasmacytic lymphoma
 - Diffuse large B-cell Lymphoma
 - Primary mediastinal lymphoma
 - Primary CNS lymphoma
 - Follicular lymphoma
 - Nodal, skin, GI, thyroid
- Age
 - Paediatric follicular lymphoma
 - Paediatric marginal zone lymphoma
 - EBV+ lymphoma of the elderly

Principles of the WHO Classification

- Lymphomas may be genetically heterogeneous
 - Follicular lymphoma
 - t(14;18)-, t(3;14)+, translocation silent
 - MALT lymphoma
 - t(1;14)/BCL10-IGH, t(11;18)/API2-MALT1, t(14;18)/IGH-MALT1
 - t(3;14)/FOXP1-IGH, t(3;14)/BCL6-IGH, t(5;14)(q34;q32)
 - t(9;14)(p11~12;q32), t(1;14)(q32;q32), t(6;7)(q25;q11), t(2;14)(p21;q32
- Lymphomas may show capacity for lineage plasticity

Review Series

THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

Steven H. Swerdlow,¹ Elias Campo,² Stefano A. Pileri,³ Nancy Lee Harris,⁴ Harald Stein,⁵ Reiner Siebert,⁶ Ranjana Advani,⁷ Michele Ghielmini,⁸ Gilles A. Salles,⁹ Andrew D. Zelenetz,¹⁰ and Elaine S. Jaffe¹¹

¹Division of Hematopathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA; ²Department of Pathology, Hospital Clinic, University of Barcelona, August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; ³Haematopathology Unit, European Institute of Oncology, Milan, and Department of Experimental, Diagnostic and Specialty Medicine, Bologna University Medical School, Bologna, Italy; ⁴Department of Pathology, Harvard Medical School and Massachusetts General Hospital, Boston, MA; ⁵Pathodiagnostik, Berlin, Germany; ⁶Institute of Human Genetics, Christian Albrechts University Kiel, Kiel, Germany; ⁷Division of Oncology, Department of Medicine, Stanford University, Stanford, CA; ⁸Department of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; ⁹Department of Hematology, Hospices Civils de Lyon, and Université Claude Bernard Lyon-1, Lyon, France; ¹⁰Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY; and ¹¹Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD

A revision of the nearly 8-year-old World Health Organization classification of the lymphoid neoplasms and the accompanying monograph is being published. It reflects a consensus among hematopathologists, geneticists, and clinicians regarding both updates to current entities as well as the addition of a limited number of new provisional entities. The revision clarifies the diagnosis and management of lesions at the very early stages of lymphomagenesis, refines the diagnostic criteria for some entities, details the expanding genetic/molecular landscape of numerous lymphoid neoplasms and their clinical correlates, and refers to investigations leading to more targeted therapeutic strategies. The major changes are reviewed with an emphasis on the most important advances in our understanding that impact our diagnostic approach, clinical expectations, and therapeutic strategies for the lymphoid neoplasms. (*Blood.* 2016;127(20):2375-2390)

THE UPDATED WHO CLASSIFICATION OF HEMATOLOGICAL MALIGNANCIES

The 2016 revision of the World Health Organization classification of
lymphoid neoplasms(Blood. 2016;127(20):2375-2390)

Steven H. Swerdlow,¹ Elias Campo,² Stefano A. Pileri,³ Nancy Lee Harris,⁴ Harald Stein,⁵ Reiner Siebert,⁶ Ranjana Advani,⁷ Michele Ghielmini,⁸ Gilles A. Salles,⁹ Andrew D. Zelenetz,¹⁰ and Elaine S. Jaffe¹¹

Table 1. 2016 WHO classification of mature lymphoid, histiocytic and dendritic neoplasms¹

Table 2. Highlights of changes in 2016 WHO classification of lymphoid, histiocytic and dendritic neoplasms (not all shown on this slide)

Makes Book Includes	
	excitational biographic graphics
Bernstein Band für	and the second se
And product all set	
Approximation of the	a productia.
theig pel supprise.	
	materies anterificite
	page annual disart prophetes -
TRN SPARATE	
previous de la	
ALL MADE AND	
Becore # Bauros	and it commented approaches the state of
a long chieve from	4
-	
- Ind. fait Real	
Revenued generation	and of respectation of the particular sectors of the particular
Participational Angeleral	
Est maintain places	
	print mainten desemant
	the products of inclusion associated and plant fitted
AM, 1 sinpounsi	
Wedder management scores	
	after test brighteen
FORCER STRATER	
· · · · ·	
Displaced land into	what hat addressed
Pasiatriga Mana	
	and the summer of
	Fee central tenders:
the fit is a large large	
In dis Interior Las 1	waters'
Share may boot a	TON LODGE THE
General Lenter &	
Advantation of the	W
Tartholicay and a	Nat Brattonations
	a obtained reserves a society of \$1001
Fitting countries 2	All the second
HIT BUIL HOP	
W. manufester	1.00 P
	Protect Elignetedian
Learnerst genu	
Princip Installers (form) any first pressors.
NUMBER OF T	
ALC: Non-Brook of	
Flandran: Impr	
Frank allowed by	
MARY JUNE, NO	r
Ballik Langington	
Autorital Sciptures	services, sale of CL and SULC and in 1914 Concerning Pro-
The part had be	particular and barrent free-often parage failly and
Hannah Population	
Amount and bit mod	
T and environmental and the	
T-init large growing	
Column and the	and the state of the south
And the set of the set of the	
Street States	Dyngtons of childrand
	des angregativentes desider"
ned field service	
	produces made test
Antonia antonia	and the second se

Minoraphy	epithetistropic imaginel 7-odi (unpriores'
	I imphapialization decider of the SP tast
They also priority	a T-cost lymphoma
	a permisalitie like T-cell tyterteme
Mycana Long	outer
fieldory sands	
	waa COOP* T-ust kmpt-girs/famitys disorders
	to id prepulsively
	internal anotheric large out lymptome
	woos vit T call tyrephone
	www.CDW' approvalve an intermetrank constant. Teal interfe
	nerver work (DDIF" T-cell (prophercut
	wour CD4" analiteation 7 cel/(analiteation discourt
	aid yrighting, 1006
	disate T-coll langhami
	ef (mphana)
	and Treat Amphonia with TPV phanotype*
	ge oil lynghana. ALX ⁺
	geost protone, ALX *
	genet promite the first of the second se
Hodgkin lympi	
	hooyte prodominant Hodgalin lynghome. Bann lynghoena
	in ronis clanaical Hostgrin lymatione
	a entrolasional tradição lympitorea
	Serily interactual interligión symptomes
	e depieted classical Herbykir tymphores
	Tyngho pioliterative dia antere (PTLI3)
	Abozinek 6.10
	nonucleose FTLD
	e Noeskole FTLD
Pelymodahik	
	PTLD di- and 1 Mill out types)
	tylin trightena #71D
	FahmaldTic ontheophaama
Heboryfe an	
	al Netscytals
Langehara	
heliamout	danation aut better
Vitor Railating	devidelic and anno no
Fullissian dan	drite out surgery.
Fibrobiantic I	elicular crél turtor
Departmenter	Delotie santogenikese
	ster chasses"



birtuine gory	15444
atar	 Composed in decision ensuring programs are non-individual to many a diagnose of \$1,5 with – (11) 27 (22) and
	 Comparison of the logity performance performance are placed programmed in the second person of the logity of the lo
	ter expert
Resource Read prepayment	nitrat belegaler tes sourd free right yourd Will-
	 A Soft cop shipman to part to be.
New of largest	 Advertiging and any in and regards of pass with DMYSMI building in their same field any UNITY for and lock DMM regards.
Automation Automatic (1)	 Middly 2009 Station in our regime of cases resulting Reports offere case must finding a feet quarter for UR.
	might MEDER as more second to LPD, and other thront produces here in reporters
full-sar areating fits	citizations are base to the unit of the local topat south in the analysis
r pé, holtoyet sergenek:	where have be in the following programs where the new of programments includence.
Federa ope H.	 I independent of an and a property control to be and a property of the second se
	 Scored, distance you obtained, in a collected statement.
Table group instances ago qual per adherent	 The common while in desirant horspeak we say in the EXX.
and the second se	a provided denotes them have an over a real number of the least resp
Realment and PL. Realments all yes PL with 1,00 answe	 Applied property with the life for the distribution. Applied for processing of William Fig. basis 2012 thereingenesis process in basis of these distributions.
Concerning and an international statements	 Production for more cause of Winek FL, term IPL2 representation of protocol particular linearity.
basi of parts, \$611	The We estima magnetical direct division building a second and
	participants participant on angels affe conceptual product with participant \$2211" and the other impact with rescand \$221 and react \$2211" and the index in product \$221.0" and the index is a second \$221.0" and
	base marker RM, capacity instruction, may become new approximate -Regiment of provide climate reporting, mark at 1914 MCCP 12, soughtest in one propriet
	al result
to pay, where the rest framework	 A 2013 MAX reprint generation in agreement of the figure (0.1 Miles) How many for an address (0.1 Miles) are already law.
Diffusion of the second s	"Defects of \$22 is \$25 as \$2 as installed on of respectationers applies
	acceptable may affeat thereas.
New Castle, 1979	Coop cases if WY and CC2 conduct two propositionals (April Control (CO)) Plantage being control of the description of the description
Here' passa, Here'	 The later options 1981," SLRC, it for relative to an interview in purport settions, school for meads 1997," Analyzing proving that test in given a more specific logicates.
the manufacture and	· Song surgered with assessed with integers foregoing printing as agreeded
hand population	The Manual Law States
Beloft the trightens with mig glassesse	 New property and part of the provide the first signature and a set of the entropy and the
	notes also deliterate lipicati
rup quie Brain ungenera, artic Mill and Bill andre 2012 Hanascatorie	 See stages to st their stage of statement the test II, an adjointed statement
Nga guda Bosti Iniginana 2020	 Deprins which is not proper in the Marke Specif Deprinse, specific (10) property in the Property constraints, which are a formulate Specific URL and Kall property statistics.
	eriorization instanting month program and type programs and types (which and \$250 to \$250 to \$250 to
	Increased on the world for here there well a \$2.1
- a va bere Adult and	 New advance compression in comparising associations E19722208 (20202) valuture is contact offic quantum and room (2010) agreement \$2,2000.
lasere BAT Lastynation et debland	where the get the prophetical associate a project where it interact street name and dealers, beaut designed a two many where all others.
hading reactificities the proprior climation	 See an angest ten integrate to produce the device banks is a bit statement with street with
	RBV trianers and a specifiety to move of the initial cautes.
Elemente accordat 1441 ataptates 8410	 Singletion and to be used for more forfers, which is type (55%, supply severally with online disease.
forements sufficiency terminal Table symptome	 Period's spectral 2011, sographical han type (2017), and grant is han serve the to inclusion-mater and lock of association with raiser process.
ration 7 day adaptation in the later.	where extends properties party with equiption in anomal mesting is said of these, some cases pro-
12 test	and the second se
presidential particula	A first suffigure data that with a mine vitro distribution for all plant forming intervention rights had no
Antial anticest of Paral Stations	 Angulart to service of a service first processing and service decision of the service method tons = 17 sets such as service together, in service analyzing
Renary generation and CBP Trail Westwood	 Toe minimi process only registly involved as unphysics in the stat.

ADDITIONAL GENETIC DATA

Hairy cell leukaemia

- BRAF V600E
- MAP2K1 in most cases that use IGHV4-34 (lack BRAF mut)

Lymphoplasmcaytic lymphoma

• MYD88 L265P

Burkitt lymphoma

- TCF3 or ID3 mutation in ≈70%
- T-cell large granulacytic leukaemia
 - STAT3 and STAT5B in subset (more aggressive behaviour)

Anaplastic lymphoma, ALK- (definite entity)

 Derrangement of region including DUSP22 and IRF4 on 6p25 associated with monomorphic appearance , lack of cytotoxic granules and superior prognosis


Principles of the WHO Classification 2016 Revision

Nomenclature influenced by clinical behaviour
 Lymphoma
 Lymphoproliferative disorder
 Neoplasia

Name Changes

- EBV+ diffuse large B cell lymphoma NOS
 - Replaces EBV+ diffuse large B cell lymphoma of elderly
 - Recognition that can be seen in younger individuals
 - Does not include EBV+ lymphomas that can be given more specific classification

Promotions




Systemic EBV+ T cell LYMPHOMA of childhood

- Promoted from lymphoproliferative disorder
- Fulminant behaviour
- Distinguish from chronic active EBV infection

Relegations

- In-situ Follicular NEOPLASIA
 - From in-situ lymphoma



 Recognition of low risk of progression to overt lymphoma


In-situ Follicular Neoplasia

- Must be distinguished from partial involvement by overt follicular lymphoma
- No follicular lymphoma in other nodes
- No previous history of follicular lymphoma

In-Situ Follicular Neoplasia

• Present in 2% of unselected LNs

- Follicular lymphoma-like B cells
 - Uncommon <18yrs
 - 70% adults >50yrs
 - Risk of progression to FL about 5%
 - Risk of progression higher if high levels of cells




Cannot be diagnosed without staining for bcl-2 protein

Is Follicular Lymphoma Preceded by ISFN?

- Pillai et al, Haematologica 2013
 - 4/4 pts with FL and previous "reactive" lymph nodes had ISFN
- Mendes et al Histopathology 2015
 - 1380 cases of FL
 - 12 previous resections with lymph nodes or extranodal lymphoid tissue
 - F:M 8:4
 - Median age at diagnosis of FL 67yrs (range 46-95)
 - 10/12 showed ISFN
 - Mean interval to FL 97.5m (range 6-264m)

Relegations


- In-situ Follicular NEOPLASIA
- In-situ mantle cell NEOPLASIA
 - From in-situ lymphoma
 - Recognition of low risk of progression to overt lymphoma



In-situ Mantle Cell Neoplasia

- Low rate of progression
- Rarer than ISFN
- Often found incidentally, sometimes in association with other NHL
- Distinguish from mantle cell lymphoma with pure mantle zone pattern

In-situ Mantle Cell Lymphoma




Is Mantle cell Lymphoma Preceded by ISMCN?

- Mendes et al Histopathology 2015
 - 126 cases of MCL
 - 2 previous resections with lymph nodes
 - F:M 1:1
 - Age at diagnosis of MCL 71 & 79yrs
 - 2/2 showed ISMCLN
 - Intervals 120m and 240m

Relegations

- In-situ Follicular NEOPLASIA
- In-situ mantle cell NEOPLASIA





- Hydroa vacciniforme-like LYMPHOPROLIFERATIVE DISORDER
 - From lymphoma
 - Relationship with chronic active EBV infection with a variable clinical course

Relegations


- In-situ Follicular NEOPLASIA
- In-situ mantle cell NEOPLASIA
- Hydroa vacciniforme-like LYMPHOPROLIFERATIVE
 DISORDER
- Primary cutaneous CD4+ small/mediumT-cell LYMPHOPROLIFERATIVE DISORDER
 - Limited clinical risk
 - Localised disease
 - Similar to clonal drug reaction

2016 Revision of WHO Classification of Lymphoma

- Hodgkin lymphoma
- Indolent B cell lymphoma
- Aggressive B cell lymphoma
- T cell lymphoma

2016 Revision of WHO Classification of Lymphoma

- Hodgkin lymphoma
- Indolent B cell lymphoma
- Aggressive B cell lymphoma
- T cell lymphoma



de Jong 2016

2016 Revision of WHO Classification of Lymphoma

- Hodgkin lymphoma
- Indolent B cell lymphoma
- Aggressive B cell lymphoma
- T cell lymphoma

Monoclonal B lymphocytosis

- Monoclonal B-cell populations in peripheral blood up to 5 x10⁹/L present for >3 months
 - CLL phenotype (75%)
 - Atypical CLL phenotype
 - Non-CLL phenotype (CD5-ve)
- Seen in up to 3.5-12% healthy individuals
 - Age <40yrs negligible
 - 90yrs 50-75%
- Virtually all cases of CLL are preceded by MBL

Monoclonal B Lymphocytosis

CD19 CD5 CD23 CD20

CLL + + + dim Atypical CLL* + + +/- bright Non-CLL + -/dim - +

*For atypical CLL cases need to exclude mantle cell lymphoma

Monoclonal B lymphocytosis Non-CLL

- CD5 dim in 20%
- Some have 7q abnormalities
 - 17% may progress to splenomegaly
 - Possibly related to splenic marginal zone lymphoma

Monoclonal B lymphocytosis


- Low count MBL
 - PB CLL < 0.5 x10⁹/l
 - Limited (if any) risk of progression to CLL
 - Does not require routine follow up
- High count MBL
 - Very similar phenotype/molecular features as Rai stage 0 CLL
 - IGVH mutated cases more frequent in CLL
 - Requires routine follow up (yearly)


Monoclonal B lymphocytosis

 CLL not diagnosed if monoclonal B-cell populations in peripheral blood with <5 x10⁹/l even with cytopaenias or disease related symptoms

Tissue-based MBL

- Cases of minimal lymph node involvement by SLL
- Cases with no proliferation centres
- Adenopathy < 15mm
- No significant risk of progression to SLL







Paediatric Follicular lymphoma

- Definite entity
- Now known as Paediatric-TYPE FL
- Not used if diffuse areas
- Median age 15-18yrs
- M:F 10:1

Paediatric Follicular lymphoma

- Large expansile, highly proliferative follicle centres
- "Blastoid" morphology
- Cases of grade 1-2 have been reported
- BM involvement not reported





Paediatric Follicular lymphoma Diagnostic Features


- Morphology
 - At least partial effacement of nodal architecture (Req)
 - Pure follicular growth pattern (Req)
 - Expansile follicles
 - Intermediate sized blasts
- Immunohistochemistry
 - BCL6+
 - BCL2-/weak (in the absence bcl-2 rearrangent)
 - Proliferation >30%
- Genetics
 - No BCL2, BCL6, IRF4 or aberrant Ig rearrangment
 - No amplification of BCL2
- Clinical
 - Stage I-II (Req)
 - Age <40
 - M>>F

Must be distinguished from conventional follicular lymphoma, grade3 in adult

• New provisional entity

- 0.05% of all DLBCL
- Clinical
 - M:F 1:1
 - Most Children
 - 71%, Median 10yrs; Range 4-28yrs [Salaverria et al BLOOD 2011]
 - Can present in adults
 - 29%; Median 61yrs: Range 31-79yrs [Salaverria et al BLOOD 2011]
- Most present in
 - Cervical lymph nodes
 - Waldeyer's ring
 - GIT

- Histology
 - Large closely packed follicles
 - Centroblasts (grade 3B) or intermediate sized bastoid cells
 - Clumped chromatin
 - Small basophilic nucleoli
 - Attenuated mantles
 - Mitoses infrequent, no starry sky pattern
 - May have follicular, follicular and diffuse or pure diffuse growth pattern



- Strong IRF4/MUM1 expression
- Usually BCL6 expression
- Lack BCL2 & CD10 in 50% cases
- Minority CD5+
- Must be distinguished from CD10-, IRF4/MUM1+ conventional FL (occur in older patients)

- Genetics
 - Lack BCL2 rearrangement (in spite of protein expression
 - IRF4 rearrangement absent in some
 - BCL6 alterations (including chromosomal breaks and mutations) can be seen
- More aggressive than paediatric FL but still good prognosis

- Outcome
 - Salaverria et al BLOOD 2011
 - All treated with chemotherapy (irrespective of growth pattern)
 - 16/17pts <30yrs alive and well (median follow up 105m)
 - Liu et al Am J Surg Pathol 2013
 - Included 2 pts treated with tonsillectomy alone
 - Disease free with up to 32m follow-up

GI Follicular lymphoma


- Duodenal-type FL
 - Most in 2nd part of duodenum
 - Multiple polyps
 - Involvement of distal SI in 80-85%
 - Distinct from other GI FL
 - Some features like ISFN
 - Some features in common with MALT lymphoma
 - Good prognosis

Testicular Follicular lymphoma


- Increased frequency in children
- Histology
 - Typical grade 3a histology
- Lack BCL2 translocation
- Good prognosis
 - Can be treated with surgery alone


Diffuse-Appearing Follicular Lymphoma

- Often large localised inguinal masses
- Largely diffuse pattern
- Low grade morphology
- Lack *BCL2* rearrangement
- Have 1p36 deletion (not specific, can be seen in conventional FL)




Young woman with a 3 cm inguinal lymphadenopathy






The tumor cells are CD23 positive

BCL2 break-apart



BCL6 break-apart




1p36 deletion (only one red signal)

Leukaemic Mantle Cell Lymphoma


- Indolent variant
- Usually involves peripheral blood, spleen and bone marrow
- SOX11 negative
- IGHV mutated (non-naïve, passed through germinal centre)
- Secondary TP53 abnormalities may occur leading to aggressive behaviour

Proposed model of molecular pathogenesis in the development and progression of major subtypes of MCL. Precursor B cells usually with but sometimes without a CCND1 rearrangement mature to abnormal naïve B cells which may initially colonize, often the inner



Steven H. Swerdlow et al. Blood 2016;127:2375-2390







2016 Revision of WHO Classification of Lymphoma

- Hodgkin lymphoma
- Indolent B cell lymphoma
- Aggressive B cell lymphoma
- T cell lymphoma

Gene Expression Profiling in DLBCL – The Gold Standard in the Definition of Sub-Diseases




Distinct biology and pathogenesis



"Germinal centre B-cell"

Activated

Hans, C. P. et al. Blood 2004;103:275-282



Burkitt Lymphoma Without MYC Rearrangement


- Does this exist?
- Recent studies have identified cases that lack MYC translocation
 - Resemble Burkitt lymphoma morphologically
 - Resemble Burkitt lymphoma phenotypically
 - Resemble Burkitt lymphoma by GEP
 - Have 11q alteration with proximal gains and telomeric losses
 - More complex karyotypes compared to Burkitt lymphoma
 - Show cytological pleomorphism, frequent nodal presentation and occasionally a follicular growth pattern
 - Similar clinical course to Burkitt lymphoma

Burkitt-like lymphoma with 11q aberration (Provisional entity)

B-cell lymphoma, unclassifiable, with features intermediate between Diffuse large B-cell lymphoma and Burkitt lymphoma

- Criteria vague
- Eliminated from revised WHO classification 2016
- All large B cell lymphomas with MYC and BCL2 and/or BCL6 rearrangments (double/triple hit) will be included in a single category
- Cases that appear blastoid or cases with intermediate morphology between DLBCL and BL but lack MYC and BCL2 and/or BCL6 rearrangements will be included in the category of HIGH GRADE B-CELL LYMPHOMA NOS

Diagnostic approach to HBCLs. Lymphomas that potentially fall into the HGBL categories can morphologically resemble B-lymphoblastic leukemia/lymphoma (B-LBL), BL, and DLBCL as well as lymphomas that are intermediate between DLBCL and BL (DLBCL/BL).




Steven H. Swerdlow et al. Blood 2016;127:2375-2390



©2016 by American Society of Hematology


Cytologic spectrum of HGBL, with MYC and BCL2 and/or BCL6 rearrangements.



Steven H. Swerdlow et al. Blood 2016;127:2375-2390




Oncogenic NF-kB Signaling in ABC DLBCL



2016 Revision of WHO Classification of Lymphoma

- Hodgkin lymphoma
- Indolent B cell lymphoma
- Aggressive B cell lymphoma
- T cell lymphoma

T cell lymphomas with T_{FH} phenotype




Quintanella-Martinez 2016

ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes

Edgardo R. Parrilla Castellar,¹ Elaine S. Jaffe,² Jonathan W. Said,³ Steven H. Swerdlow,⁴ Rhett P. Ketterling,¹ Ryan A. Knudson,¹ Jagmohan S. Sidhu,⁵ Eric D. Hsi,⁶ Shridevi Karikehalli,⁷ Liuyan Jiang,⁸ George Vasmatzis,⁹ Sarah E. Gibson,⁴ Sarah Ondrejka,⁶ Alina Nicolae,² Karen L. Grogg,¹ Cristine Allmer,¹⁰ Kay M. Ristow,¹¹ Wyndham H. Wilson,¹² William R. Macon,¹ Mark E. Law,¹ James R. Cerhan,¹⁰ Thomas M. Habermann,¹¹ Stephen M. Ansell,¹¹ Ahmet Dogan,¹ Matthew J. Maurer,¹⁰ and Andrew L. Feldman¹

Key Points


- ALK-negative ALCLs have chromosomal rearrangements of *DUSP22* or *TP63* in 30% and 8% of cases, respectively.
- DUSP22-rearranged cases have favorable outcomes similar to ALK-positive ALCLs, whereas other genetic subtypes have inferior outcomes.



Breast Implant Associated Anaplastic Large Cell Lymphoma


- Most found in seroma fluid between implant and capsule with no mass lesion
- Can be managed conservatively with removal of implant and capsule
- Some are associated with mass lesion or invasion of capsule
- Poorer prognosis need chemotherapy +/radiotherapy

Breast Implant Associated Anaplastic Large Cell Lymphoma




Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL)

- Used to be Type II Enteropathy Associated T cell Lymphoma (Type II EATL)
- Worldwide distribution but common in Asia and Hispanics
- No link to coeliac disease
- Monomorphic infiltrate of medium sized cells with clear cytopplasm and very prominent epitheliotropism
- CD56+, CD8+
- Usually $\gamma\delta$ T cell derived (78%)




Monomorphic Epitheliotropic Intestinal T-cell Lymphoma (MEITL)




Indolent T-cell lymphoproliferative disorder of the GI Tract

Most are CD8+ although CD4+ cases have been describe Indolent clinical course

Poor response to chemotherapy






Indolent CD8⁺ lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features

Danielle Greenblatt¹, Mina Ally¹, Fiona Child¹, Julia Scarisbrick², Sean Whittaker¹, Stephen Morris¹, Eduardo Calonje³, Tony Petrella⁴ and Alistair Robson³

Table 1. Clinical data


Number	Sex/age	Lesion	Location
1	F/47	Nodule and papules	Nose, hands, feet
2	F/37	Nodule	Left heel
3	F/70	Plaque	Nose
4	M/70	Ulcerated plaque	Left heel
5	F/73	Papule	Nose
6	M/68	Papule	Left ear





J Cutan Pathol 2013: 40: 248–258

Lymphoma classification cycle



HAEMATOPATHOLOGY WHAT NEXT



Revised European and American Lymphoma (REAL) Classicifation

WHO classification 2001

WHO classification 2008

WHO classification update 2016/7

WHO Lymphoma Classification 2023

